Tarsons Products (NSE:TARSONS) EBIT: ₹444 Mil (TTM As of Mar. 2026)


NSE:TARSONS Tarsons Products Ltd NSE:TARSONS
78 GF Score
Price ₹265.05
GF Value ₹564.22
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Tarsons Products EBIT?

Tarsons Products NSE:TARSONS +1.36% 78 EBIT is ₹444 Mil as of Mar. 2026. GuruFocus rates NSE:TARSONS with a GF Score™ of 78/100 and a GF Value™ of ₹564.22 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Tarsons Products's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹120 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹444 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tarsons Products's annualized ROC % for the quarter that ended in Mar. 2026 was 1.29%. Tarsons Products's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tarsons Products's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.49%.

Tarsons Products  (NSE:TARSONS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tarsons Products's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=207.6 * ( 1 - 27.53% )/( (0 + 11639.44)/ 1 )
=150.44772/11639.44
=1.29 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11858.2 - 203.12 - ( 254.06 - max(0, 2641.88 - 2657.52+254.06))
=11639.44

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Tarsons Products's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=480.84/( ( (0 + max(0, 0)) + (8315.34 + max(1531.05, 0)) )/ 1 )
=480.84/( ( 0 + 9846.39 )/ 1 )
=480.84/9846.39
=4.88 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(853.93 + 1297.83 + 251.7) - (203.12 + 0 + 669.29)
=1531.05

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tarsons Products's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=444.44/17831.041
=2.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsons Products EBIT Related Terms

Tarsons Products EBIT Historical Data

* Premium members only.

The historical data trend for Tarsons Products's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsons Products EBIT Chart

Tarsons Products Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 1,389.64 1,131.06 707.85 641.87 444.44

Tarsons Products Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.74 81.03 107.66 135.54 120.21

NSE:TARSONS vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Tarsons Products's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tarsons Products EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tarsons Products's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tarsons Products's EV-to-EBIT falls into.


NSE:TARSONS
78GF Score
Tarsons Products Ltd NSE:TARSONS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsons Products EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹444 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹444 Mil mean?
Tarsons Products (NSE:TARSONS) has a EBIT of ₹444 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tarsons Products.
Is Tarsons Products' EBIT too high?
Tarsons Products' current EBIT is ₹444 Mil. Overall, Tarsons Products has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' EBIT compare to ISRG and BDX?
Tarsons Products' EBIT of ₹444 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tarsons Products. Tarsons Products's current EBIT is ₹444 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (NSE:TARSONS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹564.22, compared to a current price of ₹265.05 — trading 53% below its estimated fair value. The current EBIT is ₹444 Mil. Tarsons Products' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Tarsons Products (NSE:TARSONS), the current EBIT is ₹444 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsons Products (NSE:TARSONS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued. The current stock price of ₹265.05 is trading 53% below its estimated GF Value™ of ₹564.22. GuruFocus considers Tarsons Products to be Significantly Undervalued.

Key valuation signals for NSE:TARSONS:

  • EBIT: ₹444 Mil
  • GF Value™: ₹564.22 vs. price of ₹265.05 (53% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the NSE:TARSONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsons Products Business Description

Other Exchanges 543399:India
Address Martin Burn Buisness Park, Room No. 902, BP- 3, Salt Lake, Sector-V, Kolkata, WB, IND, 700091
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
78GF Score

Get the complete analysis for NSE:TARSONS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹265.05
Price
₹564.22
GF Value